UNSPSC 51412301: Benziodarone

This classification denotes an antiarrhythmic agent with the molecular formula C17H12I2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75CL65GTYR, chemically known as 3,5-diiodo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl ketone but generally known as benziodarone, which bears US NIH Compound Identifier 6237. European Medicines Agency schedules Benziodarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05751MIG.

UNSPSC 51412301 Benziodarone, a Commodity code, encompasses advanced life support and emergency medications supplied to state and local health and safety agencies, including fire departments, health systems, and pharmacy benefit programs. State and local governments procure specific pharmaceutical products under this code through sealed competitive bids, cooperative purchasing agreements, and exploratory requests for information that inform future procurement strategy. Recent solicitations show municipalities and state agencies sourcing individual medication line items with firm pricing, expiration-date warranties, and delivery guarantees, alongside broader multi-source pharmaceutical programs that consolidate generic drugs and over-the-counter products for distribution across multiple jurisdictions and facility types.

The issuing bodies include municipal purchasing departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). Recent activity spans Florida, Texas, and Minnesota, with cooperative purchasing extending across multiple state and local jurisdictions. Representative opportunities include the City of Tampa Fire Rescue's sealed bid for Advanced Life Support Medications (26P00188, IFB, due April 8, 2026) soliciting Labetalol, Epinephrine, Adenosine, and Diltiazem with a one-year contract term and estimated value of $40,000; the Texas HHS Commission's RFI on Direct-to-Manufacturer Prescriptions (HHS0017013, RFI, due April 3, 2026) seeking vendor capabilities for establishing direct pharmaceutical relationships outside traditional pharmacy benefit manager and group purchasing organization channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for Generic Multi-Source Pharmaceuticals and OTC Products (S1070000015802, RFP, due March 26, 2026) establishing multi-award contracts effective July 1, 2026, across participating state and local government facilities, with price competitiveness weighted at 75 percent of evaluation criteria and administrative fees of 3 percent on all contract purchases.